



Pharmacist Shared Medicines List Release Note

31 March 2020 v1.1.1
Approved for external information
Document ID: DH-2927:2020

Related end product identifier: EP-2924:2020

The Pharmacist Shared Medicines List (PSML) clinical document type fills an important gap in managing the safety of medicines for consumers. PSML documents help ensure the continuity of medicine management for consumers across different care settings.

PSML documents allow pharmacists in both hospital and community pharmacy settings to record the outcome of consumer consultations regarding their current medications for upload to the My Health Record system.

The PSML end product leverages the Core Level One Clinical Document¹ technical specifications. The Core Level One Clinical Document is a CDA™ container for clinical information represented as a PDF document². This end product contains the PSML conformance profile and template package, which constrain the generic container document type and make it specific to the needs of PSML.

Release rationale

This version of the PSML document type supports the upload of medicines lists in PDF format. Future versions will have added support for clinical information as structured CDA content.

This is the first public release of the PSML specification. Previous releases were made available on a trial basis to limited audiences.

This version of the specification includes support for healthcare provider organisations that have received an exemption from the need to include the document author's individual healthcare provider identifier (HPI-I).

¹ <https://developer.digitalhealth.gov.au/specifications/clinical-documents/ep-2648-2018>

² CDA is a trademark of Health Level Seven International and is registered with the United States Patent and Trademark Office.

Package inclusions

Identifier	Name and version
DH-3018:2020	<i>Pharmacist Shared Medicines List – Conformance Test Specification v1.1.1</i>
DH-2761:2018	<i>Pharmacist Shared Medicines List – Implementation Guidance for Download and View PSML (B2B) v1.0</i>
DH-2762:2018	<i>Pharmacist Shared Medicines List – Implementation Guidance for Download and View PSML (Mobile) v1.0</i>
DH-2926:2020	<i>Pharmacist Shared Medicines List – My Health Record Conformance Profile v1.1.1</i>
DH-2802:2020	<i>Pharmacist Shared Medicines List – Product Data Sheet v1.1</i>
DH-2927:2020	<i>Pharmacist Shared Medicines List – Release Note v1.1.1 (this document)</i>
DH-2925:2020	<i>Pharmacist Shared Medicines List – Template Package Library v1.2</i>

Stakeholders

The following stakeholders have been involved in the development of this release:

- Commonwealth Department of Health
- National Infrastructure Operator
- State and territory health departments.

Audience

The intended audience of this document includes:

- developers and implementers of My Health Record-enabled software products
- senior managers and policy makers
- clinical experts
- health information managers
- IT operations and support teams
- system integrators.

Capabilities

The following template packages are included in the template package library of this release:

Document type variant	Conformance level	Template package ID	Template package version
HPIIRelaxed	1A	1.2.36.1.2001.1006.1.237.2	40651
Default	1A	1.2.36.1.2001.1006.1.237.1	40647

Support

For further support or to provide feedback, please email help@digitalhealth.gov.au.

Future releases

Version 2.0 of the PSML end product will include support for clinical information as structured CDA content. The Agency expects the release of PSML v2.0 in early 2021.

Additional updates may be required if issues are identified during the implementation of these specifications.

Previous releases

PSML v1.1.1 is the first public release of the PSML specification. Previous releases were made available on a trial basis to limited audiences.

Date	Version
Dec 2018	EP-2782:2018 Pharmacist Shared Medicines List v1.1 <i>(Limited release for trial use; not suitable for production use.)</i> Release rationale Document type renamed to Pharmacist <i>Shared</i> Medicines List.
Mar 2018	EP-2683:2018 Pharmacist Curated Medicines List v1.0 <i>(Limited release for trial use; not suitable for production use.)</i> Release rationale Initial release.

Publication date: 31 March 2020

Australian Digital Health Agency ABN 84 425 496 912, Level 25, 175 Liverpool Street, Sydney, NSW 2000 digitalhealth.gov.au
 Telephone 1300 901 001 or email help@digitalhealth.gov.au

Disclaimer

The Australian Digital Health Agency (“the Agency”) makes the information and other material (“Information”) in this document available in good faith but without any representation or warranty as to its accuracy or completeness. The Agency cannot accept any responsibility for the consequences of any use of the Information. As the Information is of a general nature only, it is up to any person using or relying on the Information to ensure that it is accurate, complete and suitable for the circumstances of its use.

Document control

This document is maintained in electronic form and is uncontrolled in printed form. It is the responsibility of the user to verify that this copy is the latest revision.

Copyright © 2020 Australian Digital Health Agency

This document contains information which is protected by copyright. All Rights Reserved. No part of this work may be reproduced or used in any form or by any means – graphic, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems – without the permission of the Australian Digital Health Agency. All copies of this document must include the copyright and other information contained on this page.

OFFICIAL

Acknowledgements

Council of Australian Governments

The Australian Digital Health Agency is jointly funded by the Australian Government and all state and territory governments.

HL7 International

This document includes excerpts of HL7™ International standards and other HL7 International material. HL7 International is the publisher and holder of copyright in the excerpts. The publication, reproduction and use of such excerpts is governed by the [HL7 IP Policy](#) and the HL7 International License Agreement. HL7 and CDA are trademarks of Health Level Seven International and are registered with the United States Patent and Trademark Office.